Joint Formulary & PAD

Zuranolone - Post-natal depression

You are here : Home > Formulary Search > Zuranolone - Post-natal depression

I agree that in using this database I understand that this platform only provides guidance on local prescribing policy and that all prescribing decisions are ultimately the responsibility of the clinician.

Status 1

See narrative
Formulations :
  • Capsules
Formulary Status :
Primary Care
ASPH
RSFT
SASH
SABP
Associated Icons :
NFD2
SPC
Restrictions / Comments :

Documentation

  • No records returned.

PAD Profile

ChemicalSubstance :
Zuranolone
Indication :
Post-natal depression
Group Name :
Keywords :
postnatal depression
Brand Names Include :
Zurzuvae
Important Information :

This drug has not been assessed for inclusion on the formulary. Please contact pharmacy if asked to prescribe.

Latest Additions Date From :
Latest Additions Date To :
Guidelines :
Supporting Documents :
0

Committee Recommendations (1)

05 Nov 25 - Not Set

This drug has not yet been assessed for formulary status.
It has not yet been evaluated by NICE or the Surrey Heartlands ICS Area Prescribing Committee (APC). As such, advice regarding safety, effectiveness (including cost-effectiveness) and its place in therapy is yet to be determined.
Before prescribing this drug it is recommended that clinicians contact their Pharmacy or Medicines Optimisation team to discuss possible alternatives/options.

NICE are due to publish guidance on this drug in (date to be confirmed), and this will be considered by the APC within 90 days of publication.

Other Indications

Below are listed other indications that Zuranolone is used to treat.

  • No records returned.

Other Drugs

Below are listed other drugs that are used to treat Post-natal depression.